Illustrative image – not actual.Aurobindo Pharma is planning to set up a new formulation facility, with an investment of Rs.15 crore. The facility would cater to the requirements of regulated markets.
The company has plans to enter generics business in regulated markets, and has identified 12 products in areas of cephalosporins, anti-depressants, and anti-hypertensive drugs for entry into this segment.
The Pharma is seeking US FDA approvals for its two bulk-drug plants located in Hyderabad.
